IRVINE, Calif., March 16, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. is presenting industry-leading research in precision pain medicine this week at the 2017 Annual Meeting of the American Academy of Pain Medicine (AAPM) held in Orlando, Florida, entitled, "Pain as a Public Health Issue." Using predictive analytics involving genetics, clinical, lifestyle and environmental information, Proove® researchers are presenting findings from two IRB-approved clinical studies to help reduce the epidemics of unresolved pain and prescription opioid abuse.
In the first multi-center study of 4,336 subjects, researchers found two genetic variants associated with gabapentin response. Gabapentin is a commonly prescribed non-opioid medication indicated to treat neuropathic pain. Two genetic variants, Kappa Opioid Receptor (KOR) and Corticotropin-Releasing Hormone Receptor (CRHR1), have been found to be associated with opioid and anti-depressant response. This study provides further evidence supporting Proove®'s medication response profiles which classify patients as "Likely Good Responders" versus "Likely Poor Responders." "At a time, when everyone is looking for non-opioid alternatives for patients at elevated risk for opioid use disorder, this very large study demonstrates that the use of Proove®'s precision medicine profiles can inform clinicians with additional information prior to prescribing gabapentin for pain," explains Proove®'s Director of R&D Dr. Svetlana Kantorovich.
In the E.P.I.D.E.M.I.C. study (Evaluation of Population-Based Incidences of Drug Abuse, Prescription Ethical Medication Irregularities, and Compliance Behaviors) study of 5,068 participants, researchers found that age and body mass index (BMI) are associated with the accuracy of urine toxicology testing for common opioids. Dr. Kantorovich explains, "When clinicians and law enforcement rely on urine toxicology to appropriately assess patients for drug abuse, it is important to have accurate results that consider variability in absorption, distribution, metabolism and excretion. These factors are assumed to be 'one-size-fits-all' by most labs and the science of pharmacodynamics suggests otherwise."
Proove® CEO Brian Meshkin explains, "I am so proud of our award-winning clinical research. Proove® and its research collaborators have built a stellar reputation based on facts, not opinions. This week just continues our track record of presenting results from a large IRB-approved multi-center clinical study that demonstrate statistically-significant evidence."
About Proove Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
SOURCE Proove Biosciences, Inc.